Price$14.21+3.47 (+32.64%)
2026-03-062026-06-09
News · 26 weeks70+143%
2025-12-142026-06-07
Mix3690d
- Insider20(56%)
- Other8(22%)
- SEC Filings6(17%)
- Earnings2(6%)
Latest news
25 items- INSIDERDirector Jones Christy sold $39,354 worth of shares (2,811 units at $14.00) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 27,400 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Commercial Officer Hopman Mark sold $3,385 worth of shares (275 units at $12.31) as part of a pre-agreed trading plan, decreasing direct ownership by 0.21% to 130,612 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Product Officer Mensinger Mike sold $55,194 worth of shares (4,378 units at $12.61), decreasing direct ownership by 2% to 184,415 units (SEC Form 4) (tax liability)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Commercial Officer Hopman Mark sold $67,183 worth of shares (5,329 units at $12.61), decreasing direct ownership by 4% to 130,887 units (SEC Form 4) to satisfy withholding tax4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERPresident & CEO Saint Sean sold $212,707 worth of shares (16,872 units at $12.61), decreasing direct ownership by 4% to 420,937 units (SEC Form 4) to cover taxes4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Medical Officer Russell Steven Jon sold $53,227 worth of shares (4,222 units at $12.61), decreasing direct ownership by 2% to 173,849 units (SEC Form 4) to cover withholding tax4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERChief Financial Officer Feider Stephen sold $84,165 worth of shares (6,676 units at $12.61), decreasing direct ownership by 4% to 166,053 units (SEC Form 4) to satisfy tax liability4 - Beta Bionics, Inc. (0001674632) (Issuer)
- PRBeta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public WebsiteIRVINE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-time real-world data on the iLet Bionic Pancreas is now publicly available at betabionics.com/hcp/real-world-data. The dashboard publishes outcomes for 100% of the iLet patients who meet two simple, pre-stated criteria (a provider-reported baseline HbA1c and at least two weeks of data uploaded to the cloud), with no exclusions applied. Real-world data is a key reference point for clinicians weighing multiple automated insulin delivery (AID) options. Most of the evidence in the category arrives i
- INSIDERDirector Palasis Maria was granted 16,965 shares, increasing direct ownership by 136% to 29,397 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERDirector Michel Gerard J was granted 16,965 shares, increasing direct ownership by 103% to 33,509 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERDirector Jones Christy sold $19,880 worth of shares (1,998 units at $9.95) as part of a pre-agreed trading plan and was granted 16,965 shares, increasing direct ownership by 98% to 30,211 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERDirector Dearen Danny L. was granted 16,965 shares, increasing direct ownership by 111% to 32,209 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERDirector Carney Sean was granted 16,965 shares, increasing direct ownership by 111% to 32,209 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- INSIDERDirector Lezack Adam sold $9,950 worth of shares (1,000 units at $9.95) as part of a pre-agreed trading plan, was granted 16,965 shares and sold $11,188 worth of Comon Stock (998 units at $11.21) as part of a pre-agreed trading plan, increasing direct ownership by 120% to 27,399 units (SEC Form 4)4 - Beta Bionics, Inc. (0001674632) (Issuer)
- SECBeta Bionics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Beta Bionics, Inc. (0001674632) (Filer)
- SECBeta Bionics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Beta Bionics, Inc. (0001674632) (Filer)
- PRBeta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in DevelopmentIRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration (FDA). The updated Mint commercialization timeline expectation is based on the FDA's initial responses to the company's Mint alternate controller enabled (ACE) insulin pump 510(k) application, and the progress the company has made in scaling its Mint manufacturing processes. The company expects manufacturing capacity to meet anticipated demand at launch.
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)
- PRBeta Bionics to Present at the Bank of America Securities Health Care ConferenceIRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 2:20 pm Eastern Time (11:20 am Pacific Time). A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay following the event. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the des
- SECSEC Form 10-Q filed by Beta Bionics Inc.10-Q - Beta Bionics, Inc. (0001674632) (Filer)
- SECBeta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Beta Bionics, Inc. (0001674632) (Filer)
- PRBeta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 GuidanceIRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026. First Quarter 2026 Financial Highlights & Key Metrics Net sales of $27.6 million, up 57% compared to $17.6 million in the first quarter of 2025. Durable Medical Equipment (DME) channel net sales of $16.9 million, up 22% compared to $13.8 million in the first quarter of 2025.Pharmacy Benefit Plan (PBP) channel net sales of $10.7 million, up 181% compared to $3.8 million in the fir
- SECSEC Form DEFA14A filed by Beta Bionics Inc.DEFA14A - Beta Bionics, Inc. (0001674632) (Filer)
BBNX FAQ
6 questionsWhere does BBNX stock trade?
Beta Bionics Inc. (BBNX) is listed on NASDAQ.What sector and industry is BBNX in?
Beta Bionics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Beta Bionics Inc. go public?
Beta Bionics Inc. (BBNX) completed its IPO in 2025.What are analysts saying about BBNX?
Beta Bionics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $2400.00 price target on 2026-02-09. Recent price targets range from $1600.00 to $3000.00.What companies are similar to BBNX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare BBNX side-by-side with any of them on Quantisnow.How can I track BBNX on Quantisnow?
Quantisnow aggregates Beta Bionics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BBNX to receive live email and push alerts on every new disclosure.